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Running title: Human Challenge Model of S. Paratyphi A  
 
Summary (40 words): The safe establishment of a protocol for a human challenge model for S. 
Paratyphi A can be used to expedite the evaluation of novel vaccine candidates and provides insight 
into the clinical and immune response to paratyphoid infection.  
 
 
 
 
ABSTRACT: 
Background: To expedite the evaluation of vaccines against paratyphoid fever, we aimed to develop 
the first human challenge model of S. Paratyphi A infection.  
Methods: Two groups of 20 participants underwent oral challenge with S. Paratyphi A following 
sodium bicarbonate pre-treatment at one of two dose levels (Group 1: 1-5 x 103 CFU and Group 2: 
0.5-1 x 103 CFU). Participants were monitored in an outpatient setting with daily clinical review and 
collection of blood and stool cultures. Antibiotic treatment was started when pre-specified diagnostic 
criteria were met (temperature ≥38°C for ≥12 hours and/or bacteraemia) or at day 14 post challenge.  
Results: The primary study objective was achieved following challenge with 1-5 x 103 CFU (Group 1), 
which resulted in an attack rate of 12/20 (60%). Compared with typhoid challenge, paratyphoid was 
notable for high rates of subclinical bacteraemia (at this dose 11/20; 55%). Despite limited symptoms, 
bacteraemia persisted for up to 96 hours after antibiotic treatment (median duration of bacteraemia 
53hrs; IQR 24-85hrs). Shedding of S. Paratyphi A in stool typically preceded onset of bacteraemia.  
Conclusions: Challenge with S. Paratyphi A at a dose of 1-5 x 103 CFU was well tolerated and 
associated with an acceptable safety profile. The frequency and persistence of bacteraemia in the 
absence of clinical symptoms was notable, and markedly different from that seen in previous typhoid 
challenge studies. We conclude that the paratyphoid challenge model is suitable for the assessment 
of vaccine efficacy using endpoints that include bacteraemia and/or symptomatology.  
Clinicaltrials.gov Registration: NCT02100397 
Keywords: Paratyphoid Infection, Enteric Fever, Salmonella enterica Paratyphi A, Human challenge 
study, Immune responses 
  
 
 
Introduction 
Efforts aimed at reducing the global burden of enteric fever are likely to require a co-ordinated 
strategy comprising improvements in water quality, sanitation and hygiene measures along with the 
development of effective vaccines. Whilst Salmonella Typhi remains the principal aetiological agent 
of enteric fever globally, Salmonella enterica serovar Paratyphi A (S. Paratyphi A) is responsible for an 
increasing proportion of enteric fever cases.  In South and South-East Asia, annual incidence rates in 
some areas are estimated to be as high as 150 cases/100,000 person-years.[1]   
Relatively little is known regarding the pathophysiology and host response to S. Paratyphi A infection. 
Salmonella enterica serovars Typhi and Paratyphi A possess similar genomic markers of host-
restriction, but differ with regards to expression of certain virulence factors, such as the lack of Vi 
polysaccharide capsule expression by S. Paratyphi A/B. [2,3] Additionally, there are currently no 
licensed vaccines available for the prevention of paratyphoid fever. The licensed S. Typhi vaccine 
Ty21a can induce cross-reactive humoral immune responses to S. Paratyphi A/B in vitro and there is 
some evidence from field trials for cross protection against S. Paratyphi B.[4,5] Several promising 
vaccine candidates are in development, including live-attenuated strains and conjugate vaccines 
targeted against the O-specific polysaccharide (O:2) of S. Paratyphi A, although no candidate 
vaccines have undergone efficacy trials to date.[6] Development of vaccines to prevent paratyphoid 
infection is hampered by limited knowledge of immunological correlates of protection and the lack 
of a suitable small-animal model of infection. 
Human challenge studies are increasingly used to identify promising vaccine candidates suitable for 
evaluation in large-scale field trials.[7] In this study, we sought to establish a S. Paratyphi A human 
challenge model in healthy adult volunteers by oral challenge to enable future assessment of S. 
Paratyphi A vaccines and to assess host-pathogen interactions under a strictly controlled setting.  
 
Methods 
Study Design  
We performed an observational, dose-level modification human challenge study of S. Paratyphi A 
infection conducted in healthy community adult volunteers, at the Centre for Clinical Vaccinology and 
Tropical Medicine, University of Oxford, Oxford, United Kingdom.[8] Description of the study protocol 
and enrolment criteria are detailed elsewhere.[9][10] 
 
 
The primary objective of the study was to determine the dose in CFU of S. Paratyphi A strain 
NVGH308 required to achieve an attack rate of 60–75%, when ingested with sodium bicarbonate 
solution to neutralise gastric acid. 
 
Challenge strain  
S. Paratyphi A strain NVGH308, was isolated in 2006 from a patient with paratyphoid fever in 
Kathmandu, Nepal, and is susceptible to most commonly used antibiotics, including ciprofloxacin 
(Supplementary Table 1).[9] The NVGH308 strain was selected as it is a contemporary, circulating 
strain isolated from a patient in a highly endemic country.  
 
Whole genome sequencing was undertaken to identify the phylogenetic relationship of NVGH308 to 
other circulating strains (Supplementary Figure 1; Supplementary Methods). 
 
The challenge inoculum was freshly prepared on day of challenge (Supplementary Methods). An initial 
target dose of 1-5 x 103 CFU (Group 1) was selected based upon prior S. Typhi challenge studies in a 
similar study population.[11] Following fulfilment of the primary objective at the initial target dose, 
we amended the original study protocol to include a dose de-escalation group (0.5-1 x 103 CFU; 
Group 2) in order to affirm a relationship between dose and diagnostic endpoints.  
 
Clinical Evaluation 
Regular participant safety monitoring occurred through daily clinical review for a minimum of 14 days 
and included solicited symptoms (Supplementary Table 2) and twice daily temperature 
measurements.[9] 
Diagnostic Criteria 
The primary outcome was the rate of paratyphoid infection, defined as a positive blood culture for S. 
Paratyphi A (taken ≥72 hours after challenge to avoid detection of primary bacteraemia) and/or oral 
temperature ≥38°C persisting for ≥12 hours. [9] Treatment was initiated upon fulfilment of diagnostic 
criteria (or at day 14 for those without illness) and comprised oral ciprofloxacin 500mg twice daily for 
14 days.  
Serological Response 
 
 
Blood was collected at baseline and day 10, 28 and 90 post challenge. Specific Immunoglobulin M 
(IgM), IgG and IgA to S. Paratyphi A lipopolysaccharide (LPS) and flagellin (H) were measured by an in-
house enzyme-linked immunosorbent assay (ELISA) using goat anti-human IgM, IgG and IgA 
conjugated to horseradish peroxidase (see Supplementary Methods).  
Statistical Analysis 
All participants were included in the primary analysis and a post-hoc analysis was conducted 
comparing participants challenged with S. Paratyphi A in this study with those challenged with S. 
Typhi in our previous study.[11] 
Clinical, laboratory and immunological data were collated using a clinical trials database (OpenClinica, 
version 3.1). Data analysis was performed as described in detail in the Supplementary Methods, using 
R version 3.2.2.[12]  
 
Results 
Forty healthy adult participants were enrolled into the study between 20th May and 20th November 
2014. (Table 1; Supplementary Figure 2). Twenty participants were challenged with S. Paratyphi A at 
a target dose of 1-5 x 103 CFU (group 1). A second group of twenty participants was challenged at a 
target dose of 0.5-1.0 x 103 CFU (group 2).  
Paratyphoid infection was diagnosed in 20/40 (50%) of all participants challenged. The primary study 
objective was achieved in challenge group 1, where 12/20 participants met the pre-specified 
diagnostic criteria for paratyphoid fever (Attack rate 60%; 95%CI 36–81%) (Figure 1). Eleven 
participants (11/12, 92%) in this group were diagnosed following a positive blood culture for S. 
Paratyphi A and one was diagnosed based on temperature criteria with subsequent blood culture 
confirmation. Median time from challenge to initiation of treatment was 6.4 days (range 5.9-8.3 days) 
(Table 2).  
Paratyphoid infection was diagnosed less frequently in challenge group 2. In this group, 8/20 
participants met the pre-specified diagnostic criteria following challenge (Attack rate 40%; 95%CI 19-
64%), all of whom were diagnosed following a positive blood culture (Table 2). Median time from 
challenge to initiation of treatment was 8.3 days (range 7.1-12.0 days) (Figure 1).  
Attack rates using alternative diagnostic criteria are outlined in Table 2. The hypothetical attack rate 
was lower in both study groups if clinical end-points alone (e.g. fever) were used to define 
paratyphoid disease. 
 
 
All participants were managed with daily clinical review and no participants met the pre-specified 
criteria for severe enteric fever.[9] Two participants had positive stool cultures for S. Paratyphi A after 
completing a 14-day course of ciprofloxacin, neither of whom had evidence of gall-bladder disease at 
screening. Both were successfully re-treated with a 14-day course of oral azithromycin (500mg daily) 
and all subsequent clearance stools were negative. There were no episodes of relapse of clinical 
disease.[9] One serious adverse event was recorded (appendicitis six months after S. Paratyphi A 
challenge) and was assessed as being unrelated to study procedures. One participant developed 
mouth ulcers after treatment with ciprofloxacin, which resolved following a change to azithromycin. A 
second participant developed vaginal candidiasis following antibiotic treatment (ciprofloxacin), which 
resolved following treatment with topical clotrimazole.  
The most common symptom reported by those with paratyphoid illness was headache (17/20; 85%), 
followed by malaise (15/20; 75%), abdominal pain (14/20; 70%) and myalgia (14/20; 70%). The 
majority of solicited symptoms were graded as mild and did not result in limitation of usual activity 
(Figure 1, Supplementary Table 2).  In comparison with participants challenged with S. Typhi in 
earlier studies,[11] paratyphoid resulted in a milder symptom profile, characterised by fewer severe 
symptoms and lower cumulative symptom scores (Figure 2, Supplementary Table 3).  
Laboratory parameters were in keeping with those expected for acute enteric fever (Supplementary 
Figure 3).[13] Amongst those meeting diagnostic endpoints, peripheral blood biochemistry 
demonstrated elevated C-reactive protein and alanine aminotransferase, whilst haematology 
revealed a modest fall in haemoglobin, neutrophil and lymphocyte counts. 
We documented at least one positive blood culture in all participants diagnosed with paratyphoid 
(20/20; 100%; median number positive blood cultures 5.5, range 1-8). Median bacteraemia clearance 
times were 2.2 days (IQR 1-3.5 days) for S. Paratyphi (Figure 2, Figure 3).  The median time from 
challenge to bacteraemia was 5.2 days (interquartile range [IQR], 5.0-6.4) in group 1 and 7 days (IQR 
6.7-7.4) in group 2. Quantitative blood cultures performed prior to antibiotic treatment demonstrated 
median bacterial loads of 1.1 CFU/ml (range 0-4.1), in group 1 and 0.2 CFU/ml (range 0-6.9) in group 2 
participants, which are comparable to those seen in cases of typhoid fever in earlier challenge studies 
and in endemic settings.[11,14] The rate of blood culture positive days was twice as high in S. 
Paratyphi A diagnosed participants than in S. Typhi diagnosed participants from our previous study 
(IRR 2.1; 95%CI 1.46 to 3.1, p<0.001) (Figure 2; Table 2).  
Sub-clinical bacteraemia was a common finding following challenge, with 11/20 (55%; 95%CI 32-77%) 
participants having demonstrable bacteraemia but remaining persistently afebrile following 
challenge, although other symptoms were observed as discussed above (Supplementary Table 2). 
 
 
Afebrile bacteraemia was less common than in earlier typhoid challenge studies performed by our 
group (4/21; 19%; 95%CI 5-42%; p=0.025 Fisher’s exact test).[11] Fever was recorded less frequently 
in group 2 (2/8; 25%) than in group 1 (7/12; 58%) (Table 2).  
Shedding of S. Paratyphi A in stool occurred sporadically throughout the challenge period and at least 
one stool cultures was positive in 17/40 participants (43%; 95%CI 27-59%) (Figure 3). Amongst 
participants with demonstrable bacteraemia 11/20 (55%; 95%CI 32-77%) had a positive stool culture  
for at least one time point and stool shedding frequently preceded the onset of bacteraemia (Figure 
3). Asymptomatic shedding was identified in 6/20 participants (30%; 95%CI 12-54%) who did not 
reach the diagnostic criteria during the observation period.  The rate of stool positivity was similar in 
S. Paratyphi A diagnosed participants as was observed previously in S. Typhi diagnosed participants 
(IRR 0.78; 95%CI 0.40 to 1.52, p=0.457).  
Baseline anti-LPS IgG geometric mean concentrations were higher in undiagnosed participants prior 
to challenge (p=0.034) but did not relate to the incidence of bacteraemia (Supplementary Figure 4). 
Anti-LPS antibody responses peaked at day 28 post-challenge and were significantly higher in those 
diagnosed with paratyphoid compared with those without acute disease (p<0.001). In contrast, anti-H 
antibody responses were only marginally increased above baseline at D28 and only in those meeting 
diagnostic endpoints (Supplementary Figure 4).  
 
Discussion  
In 1909, Proescher reported a case of “two individuals who accidentally swallowed a small amount of 
a pure culture” of Salmonella Paratyphi A and who “became ill…five and seven days after imbibing” 
the culture.[15] Here, we describe the first deliberate and controlled human challenge model using a 
contemporary circulating strain of S. Paratyphi A. Whilst S. Typhi challenge studies have become well 
established over the past half-century, we have uniquely demonstrated that S. Paratyphi A challenge 
can also be undertaken safely in an outpatient setting. Challenge at a target dose of 1-5x103 CFU was 
sufficient to achieve an attack rate of 60% in a cohort of naïve volunteers, whilst challenge using a 
lower dose resulted in a reduced attack rate and increased time to bacteraemia.  
Whilst Vi-conjugate typhoid vaccines are currently licenced in both India and China, the paratyphoid A 
vaccine pipeline is less well developed.[6] The effect of future Vi-based typhoid vaccine programmes 
on the burden of paratyphoid fever is unknown and there is conflicting evidence of serovar 
replacement following historical typhoid vaccination campaigns.[16,17] This presents a pressing need 
for accelerated paratyphoid A vaccine development, which could be facilitated by the establishment 
of a human paratyphoid A challenge model. In support of this, the WHO has stated that well-validated 
 
 
challenge studies can provide “considerable supporting evidence of the efficacy” of typhoid Vi-
conjugate vaccines, as well as offering insights into immunological correlates of protection.[18] We 
suggest that the model described herein could fulfil an equivalent role for paratyphoid by providing a 
platform to assess the efficacy of paratyphoid vaccines currently in development.  
The choice of diagnostic endpoints is central to future applications of this model in the assessment of 
candidate paratyphoid vaccines. In this study, we used a composite diagnostic end-point of clinical 
and/or microbiologically defined paratyphoid infection and observed that 95% of individuals who met 
the diagnostic criteria did so based upon microbiological criteria (Table 2). The frequency of blood 
culture sampling in this study resulted in the identification of several cases of asymptomatic 
bacteraemia, which may or may not have progressed to symptomatic paratyphoid fever if left 
untreated. Whilst the consistent finding of bacteraemia represents an unambiguous diagnostic 
endpoint, this could set an overly stringent threshold in future vaccine efficacy studies and clinical 
endpoints might be preferable as this more accurately reflects the situation in the field (Table 2). 
Arguably, vaccines demonstrating at least moderate efficacy in this challenge model would perform 
better in field trials, where the endpoints would include a clinical syndrome of paratyphoid fever with 
culture confirmation. Vaccine efficacy studies using this model should include multiple alternative 
pre-specified secondary diagnostic endpoints, such as the proportion of cases diagnosed by clinical 
criteria alone, microbiological criteria alone or a composite of clinical symptoms with culture 
confirmation.  
To our knowledge, no previous studies have explored the infectious dose required to induce 
paratyphoid disease, although it is frequently assumed that S. Paratyphi A requires a higher dose of 
bacteria to cause clinical disease than does S. Typhi.[19,20] In this study, an attack rate of 60% was 
achieved using a dose of 1-5x103 CFU S. Paratyphi A, which is comparable to the attack rate (55%) 
observed at an equivalent dose of S. Typhi in earlier studies.[11] Notably challenge with as few as 700 
CFU S. Paratyphi A was able to induce acute disease, in the context of sodium bicarbonate pre-
treatment. Our findings are broadly consistent with observations from S. Typhi challenge studies, 
where reducing the challenge inoculum results in a reduced attack rate and longer incubation 
period.[21] As with S. Typhi, it is possible that the infectious dose required to induce paratyphoid 
disease in a non-endemic setting may differ from that required in an endemic setting, where prior 
exposure could lead to partial immunity.  
We performed a post-hoc comparison of symptom data collected during earlier typhoid challenge 
studies [11] and noted that paratyphoid challenge resulted in a milder disease profile than that 
previously observed following typhoid challenge. In our model, paratyphoid was characterised by high 
 
 
rates of afebrile bacteraemia in groups 1 and 2 (11/20; 55%) with minimal symptoms, which may 
otherwise have escaped detection in the absence of intensive sampling. Case series from the pre-
antibiotic era reported that S. Paratyphi A caused a spectrum of clinical manifestations that “closely 
resembles that of mild enteric fever” [22] and asymptomatic cases of paratyphoid infection are well 
described.[23,24] Although the largest published case series to date indicates that S. Typhi and 
Paratyphi A infections cause an indistinguishable clinical syndrome[19], this study was limited to 
patients who attended healthcare facilities and may not account for ambulatory or mild cases of 
paratyphoid in the community. In keeping with this, epidemiological data from endemic settings 
suggest that sub-clinical paratyphoid infection frequently occurs.[5] In light of our challenge model 
data, we interpret earlier data as being supportive of the hypothesis of an underappreciated and 
undiagnosed burden of paratyphoid disease in the community. In a proportion of individuals, 
exposure to the bacillus is followed by asymptomatic bacteraemia and asymptomatic stool shedding, 
potentially perpetuating both long- and short-cycle transmission. In keeping with this, asymptomatic 
shedding of S. Paratyphi A was also observed in our model, including in individuals who did not meet 
diagnostic criteria for paratyphoid disease.  
Somewhat counter-intuitively, we observed prolonged bacteraemia and protracted time to blood 
culture clearance (≥96hrs) in the paratyphoid challenge model, despite the low rate of fever. In 
addition, convalescent stool shedding was noted in two individuals despite a 14 day course of 
ciprofloxacin, both of whom were successfully treated with a further course of azithromycin. The 
relatively poor response to ciprofloxacin was unexpected, given that the NVGH308 strain is sensitive 
to ciprofloxacin according to current CLSI and EUCAST guidelines (MIC 0.06 μg/ml). [25,26] Studies in 
endemic settings have found fluoroquinolone MICs for S. Paratyphi A were typically higher than those 
for S. Typhi.[19] The mechanisms underlying the discrepancy between the clinical and microbiological 
profiles of paratyphoid infection seen in this study are unclear, but may represent a strategy of 
achieving infection-by-stealth that facilitates onward transmission and persistence of the bacterium 
within the environment.  
Ethical and safety considerations in the design of this study, including early initiation of rescue 
therapy, limit the extent that our findings can be extrapolated to endemic settings. For example, a 
proportion of individuals with sub-clinical bacteraemia could have progressed to symptomatic disease 
had antibiotic treatment been delayed, as was observed in historical typhoid challenge studies.[27] As 
only a single strain was used in this study we cannot conclusively rule out a strain-specific effect for 
our observations. However, the NVGH308 strain is a recent clinical isolate from a symptomatic case 
with bacteraemia, and is closely related to currently circulating strains in South Asia. Additionally, S. 
Paratyphi A is a clonal monomorphic pathogen containing limited genomic variation, suggesting that 
 
 
the pathogenicity and immune response to the NVGH308 strain will translate to other wild-type 
strains.[28] Future work could identify whether these observations apply to other strains of S. 
Paratyphi A and also investigate B and C strains in the human challenge model. The evaluation of only 
two challenge doses is one potential limitation of this study and challenge at of higher dose ranges 
and/or re-challenge studies could be undertaken to better define clinical outcomes.  
In summary, we have established the first S. Paratyphi A human challenge model and have described 
the clinical and microbiological response to challenge in healthy adult volunteers, presenting marked 
differences from those previously seen with S. Typhi. Whilst S. Typhi challenge models have existed 
for several decades, the need for a S. Paratyphi A challenge model arguably exceeds that for S. Typhi, 
as far less is understood regarding the responses to infection and there are no specific control 
measures yet available. Development of a successful paratyphoid challenge model could offer 
distinctive insights into paratyphoid disease as well as providing a platform to expedite the 
development and implementation of much needed vaccines and diagnostics. 
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Figure Legends 
  
Figure 1 
(a)Kaplan-Meier plots indicating time to diagnostic end points (i) Time to diagnosis (ii) Time to first 
temperature ≥38°C. (b) Clinical symptom profiles following S. Paratyphi A challenge. Percentage of 
participants reporting solicited systemic symptoms on one or more days following S. Paratyphi A 
challenge, recorded using an online diary for 21 days. Stacked columns display percentage of 
participants reporting maximum symptom severity as mild, moderate or severe. Individuals meeting 
pre-specified criteria for paratyphoid disease in group 1 (i) and group 2 (ii) Individuals who did not 
meet pre-specified criteria for paratyphoid disease in group 1 and group 2. None = No reported 
symptoms; Mild = Present but no limitation of usual activity; Moderate =some limitation of daily 
activity; Severe = unable to perform normal daily activity. 
Figure 2 
Comparison of the clinical and microbiological response to S. Typhi and S. Paratyphi A challenge. (a) 
Solicited systemic symptoms in individuals with acute typhoid (T, n=24) or paratyphoid (P, n=20) 
disease recorded using an online diary (Day 0 = Day of challenge; Day 14 = Final day of treatment 
initiation). Percentage of participants reporting one or more events. Stacked columns display 
percentage of participants reporting maximum symptom severity as mild (present but no limitation of 
usual activity), moderate (some limitation of daily activity) or severe (unable to perform normal daily 
activity); (b) Comparison of cumulative symptom severity scores between participants with acute 
typhoid (T, n=24) or paratyphoid (P, n=20) disease. Symptoms scores were calculated by summing 
numerical values assigned to the severity of individual symptoms between Day 0 to Day 14 (0=not 
present; 1=mild; 2=moderate; 3=severe). Box-and-whiskers display median, IQR and range; (c) 
Symptom severity scores for specific symptoms Day 0 to Day 14; (d) Results of quantitative blood 
 
 
cultures (CFU/ml) collected immediately prior to initiation of antibiotic treatment for participants with 
typhoid or paratyphoid disease (See Materials & Methods).  
 
Figure 3 
Clinical and Microbiological dynamics for participants challenged with S. Typhi and S. Paratyphi A. 
PD1-20 = Confirmed paratyphoid disease; nPD1-20 = Paratyphoid disease not diagnosed. TD1-TD25 = 
Confirmed typhoid disease; nTD1-nTD16 = Typhoid disease not diagnosed. Day 0 = Day of challenge. 
(a) Pattern of blood culture results (red = positive; grey = negative; white = sample not collected). 
Numbers in parenthesis refer to quantitative blood culture colony county (CFU/ml) taken immediately 
prior to antibiotic treatment and correspond to day of treatment initiation; (b) Pattern of stool 
shedding following challenge. Coloured squares indicate stool culture results for S. Paratyphi A or S. 
Typhi (brown = positive; grey = negative; white = sample not collected). Tx = Day of treatment 
initiation. (c) Maximum temperature measurements by day. Tx= Day of treatment initiation 
  
 
  
 
 
Table 1  
Participant demographic characteristics 
Characteristic Group 1 Group 2 All 
No. of participants 
challenged 
20 20 40 
Sex, Male, No (%) 10 (50) 11 (55) 21 (52.5) 
Age, y, Median (Range) 27 (19-49) 23 (20-50) 25(19 -50) 
Ethnicity, White British, No 
(%) 
18 (90) 17 (85) 35 (88) 
Country of Birth, UK, No (%) 15 (75) 17 (85) 32 (80) 
Tobacco Smoking, Yes, No (%) 9 (45) 8 (40) 17 (43) 
Alcohol Intake, Units/week, 
Median (IQR) 
4 (0-10) 7 (4-11) 5 (2-10) 
BMI, kg/m
2
, Mean ± SD 23.5 ± 3.2 22.8 ± 4.2 24.1 ± 3.8 
 
  
 
 
Table 2  
Attack rates and response to S. Paratyphi A challenge 
 
Results 
 
Group 1 
(n=20) 
Group 2  
(n=20) 
All  
(n=40) 
Target challenge dose (CFU) 1-5x10
3
 0.5-1x10
3
 - 
Attack Rate, n (% total) (95% 
confidence interval) 
12 (60) 
(36-81) 
8 (40)  
(19-64) 
20 (50)  
(34-66) 
Actual challenge dose, CFU 
x10
3
, median, range 
2.4 (2.2-2.8) 0.9(0.7-1.3) - 
Paratyphoid A diagnosed 2.4 (2.2-2.7) 1.0 (0.7-1.3) - 
Paratyphoid A NOT 
diagnosed 
2.5 (2.3-2.7) 0.8 (0.7-1.3) - 
Actual challenge dose/Body 
surface area
a
, CFU/m
2 
Mean ± 
SD 
1350 ± 166 519 ± 163 - 
Paratyphoid A diagnosed 1336 ± 196 533 ± 171 - 
Paratyphoid A NOT 
diagnosed 
1371 ± 119 509 ± 165 - 
Mode of diagnosis, n (% 
total) 
   
Temperature ≥38°C for ≥12 
hours with blood culture 
1 (5) 0 (0) 1 (2.5) 
 
 
confirmation 
Microbiological diagnosis
b
 11 (55) 8 (40) 19 (47.5) 
Bacteraemia, n (% total) 12 (60) 8 (40) 20 (50) 
Time to bacteraemiac, days, 
median  (interquartile range)  
5.2 (5.0-6.4) 
 
7 (6-11) 
 
6.1 (5.1-7.1) 
 
Time to antibiotics
d
, days, 
median  (interquartile range) 
6.4 (6.2-7.4) 
 
8.3 (8.2-9.2) 
 
8.0 (6.4-8.3) 
 
Overall duration of 
bacteraemiae, days, median 
(interquartile range) 
4.1 (3.4-5.0) 
 
1.0 (1.0 -3.4) 
 
4.0 (1.1-4.9) 
 
Clearance timef, days, median 
(interquartile range) 
2.9 (2.1-3.6) 
 
0.9 (0.7-1.9) 
 
2.2 (1.0-3.5) 
 
Quantitative blood culture, 
CFU/ml, Median (range) 
1.1 (0-4.1) 0.2 (0-6.9) 1 (0-6.9) 
Temperature ≥38°C any 
durationg, n (% total) 
7 (35) 2 (10) 9 (45) 
in Paratyphoid A diagnosed 7 (35) 2 (10) 9 (45) 
in Paratyphoid A NOT 
diagnosed 
0 (0) 0 (0) 0 (0) 
Stool Shedding, n (% total) 12 (60) 4 (20) 16 (40) 
in Paratyphoid A diagnosed 8 (40) 2 (10) 10 (25) 
in Paratyphoid A NOT 
diagnosed 
4 (20) 2 (10) 6 (15) 
 
 
Attack rates using alternative 
diagnostic criteria 
   
Temperature ≥37.5°C (any 
duration), n (% total) 
8 (40) 4 (20) 12 (30) 
Temperature ≥38°C (any 
duration), n (% total) 
7 (35) 2 (10) 9 (45) 
Temperature ≥37.5°C (any 
duration) AND positive blood 
culture 
7 (35) 4 (20) 11 (27.5) 
Temperature ≥38°C (any 
duration) AND positive blood 
culture 
7 (35) 2 (10) 9 (22.5) 
a. Body surface area calculated according to Mostellar Method, BSA (m2) = (height cm x weight kg/3600) x 0.5 
b. Salmonella Paratyphi A isolated from blood culture taken ≥72hours from challenge 
c. Time from challenge to collection of first positive blood culture.   
d. Time from ingestion of the challenge agent to the fulfilment of diagnostic criteria.  
e. Time from collection of first positive blood culture to collection of first persistently negative blood culture. 
f. Time from initiation of antibiotics to time the collection of first persistently negative blood culture. 
g. Day 0 (Day of challenge) to Day 14. 
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